Cortexyme, Inc. (CRTX) |
| 1.95 0.05 (2.63%) 08-01 00:00 |
| Open: | 1.91 |
| High: | 1.97 |
| Low: | 1.86 |
| Volume: | 272,208 |
| Market Cap: | 70(M) |
| PE Ratio: | -0.66 |
| Exchange: | NASDAQ Global Select |
| Industry: | Biotechnology |
| Sector: | Healthcare |
| Technical analysis | ||||
 |
||||
| sell | buy | |||
| Resistance 2: | 2.30 |
| Resistance 1: | 1.97 |
| Pivot price: | 1.95 |
| Support 1: | 1.90 |
| Support 2: | 1.86 |
| 52w High: | |
| 52w Low: |
Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Financials
| EPS | -2.963 |
| Book Value | 3.530 |
| PEG Ratio | -0.04 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -37.5 |
| Return on Equity (ttm) | -67.3 |
Company news
Sat, 10 Jan 2026
Cortexyme (NASDAQ:CRTX) Share Price Crosses Above Two Hundred Day Moving Average – Here’s Why - Defense World
Sun, 28 Dec 2025
Cortexyme (NASDAQ:CRTX) versus Eloxx Pharmaceuticals (NASDAQ:ELOX) Critical Contrast - Defense World
Wed, 27 Jul 2022
San Gabriel Valley Tribune - FinancialContent
Mon, 14 Feb 2022
Silicon Valley - FinancialContent
Tue, 01 Feb 2022
After Alzheimer's drug flop, Peninsula biotech's founding execs exit - The Business Journals
Wed, 27 Oct 2021
Alzheimer’s Disease Stock Cortexyme Craters on Trial Failure - Bloomberg.com
 StockChart iOS |
 StoxlineLite iOS |
StoxlineLite iOS |
 OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |
